London · Delayed Price · Currency is GBP · Price in SEK Oncopeptides AB Statistics
Total Valuation
Oncopeptides AB has a market cap or net worth of GBP 103.78 million. The enterprise value is 102.06 million.
| Market Cap | 103.78M |
| Enterprise Value | 102.06M |
Important Dates
The last earnings date was Wednesday, November 5, 2025.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 258.57M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +58.45% |
| Shares Change (QoQ) | +7.65% |
| Owned by Insiders (%) | 0.70% |
| Owned by Institutions (%) | 16.59% |
| Float | 229.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.04 |
| PB Ratio | 201.06 |
| P/TBV Ratio | 201.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.83 |
| EV / Sales | 20.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.66 |
Financial Position
The company has a current ratio of 3.42, with a Debt / Equity ratio of 19.30.
| Current Ratio | 3.42 |
| Quick Ratio | 3.27 |
| Debt / Equity | 19.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.55 |
| Interest Coverage | -19.40 |
Financial Efficiency
Return on equity (ROE) is -376.73% and return on invested capital (ROIC) is -79.61%.
| Return on Equity (ROE) | -376.73% |
| Return on Assets (ROA) | -57.86% |
| Return on Invested Capital (ROIC) | -79.61% |
| Return on Capital Employed (ROCE) | -158.10% |
| Revenue Per Employee | 65,756 |
| Profits Per Employee | -281,949 |
| Employee Count | 80 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 0.20 |
Taxes
In the past 12 months, Oncopeptides AB has paid 80,688 in taxes.
| Income Tax | 80,688 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +140.38% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +140.38% |
| 50-Day Moving Average | 5.22 |
| 200-Day Moving Average | 3.11 |
| Relative Strength Index (RSI) | 40.71 |
| Average Volume (20 Days) | 33,347 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncopeptides AB had revenue of GBP 4.93 million and -21.15 million in losses. Loss per share was -0.10.
| Revenue | 4.93M |
| Gross Profit | 4.83M |
| Operating Income | -19.39M |
| Pretax Income | -21.07M |
| Net Income | -21.15M |
| EBITDA | -19.19M |
| EBIT | -19.39M |
| Loss Per Share | -0.10 |
Balance Sheet
The company has 11.68 million in cash and 9.96 million in debt, giving a net cash position of 1.71 million.
| Cash & Cash Equivalents | 11.68M |
| Total Debt | 9.96M |
| Net Cash | 1.71M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 516,182 |
| Book Value Per Share | 0.00 |
| Working Capital | 10.69M |
Cash Flow
In the last 12 months, operating cash flow was -17.99 million and capital expenditures -28,186, giving a free cash flow of -18.02 million.
| Operating Cash Flow | -17.99M |
| Capital Expenditures | -28,186 |
| Free Cash Flow | -18.02M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 97.88% |
| Operating Margin | -393.09% |
| Pretax Margin | -427.15% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oncopeptides AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -58.45% |
| Shareholder Yield | -58.45% |
| Earnings Yield | -20.38% |
| FCF Yield | -17.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |